THE WORLD MARKET FOR ANTI-INFECTIVES.pdf
《THE WORLD MARKET FOR ANTI-INFECTIVES.pdf》由会员分享,可在线阅读,更多相关《THE WORLD MARKET FOR ANTI-INFECTIVES.pdf(253页珍藏版)》请在三一文库上搜索。
1、Anti-Infectives February 2012 Kalorama Information A division of MarketR 38 East 29th Street Sixth Floor New York, New York 10016 212.807 .2660 t 800.298.5603 t 212.807 .2676 f Copyright 2012 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereaf
2、ter developed, in whole or in any part, is strictly prohibited. THE WORLD MARKET FOR ANTI-INFECTIVES Anti-Infectives: A Global Market Overview has been prepared by Kalorama Information. We serve business and industrial clients in the United States and abroad with a complete line of information servi
3、ces and research publications. Kalorama Information Market Intelligence Reports are specifically designed to aid the action- oriented executive by providing a thorough presentation of essential data and concise analysis. Author: Melissa Elder Publication Date: February 2012 38 East 29th Street New Y
4、ork, New York 10016 (800) 298- 5699 Outside the U.S. (212) 807- 2657 FAX: (212) 807- 2676 www.KaloramaI E- MAIL: Copyright 2012 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited.
5、TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY 1 Introduction . 1 Scope and Methodology . 2 Total Size and Growth of the Market . 4 Issues and Trends Affecting Market . 6 Leading Competitors . 7 CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS .9 Overview . 9 Introduction to Pathogens . 9 Demographic
6、s of the World 11 Life Expectancy 12 Infections and Drug Resistance 15 Causes of Drug Resistance 16 Drug Resistance in Select Populations . 17 Measures for Reducing Resistance . 18 HIV Trends . 20 Manufacturer and Marketer Trends 25 Trends in Partnerships and Alliances 25 Developers Trends 25 Aradig
7、m 27 ARD- 3100 . 27 Phase II 27 Cystic fibrosis . 27 ARD- 3150 . 27 Phase II 27 Bronchiectasis . 27 ARD- 1100 . 27 Preclinical . 27 Inhalation anthrax . 27 Trends in Rx- to- OTC Switches 40 CHAPTER THREE: ANTIFUNGAL DRUGS .43 Overview . 43 Types of Fungal Infections . 44 Superficial . 44 Systemic 45
8、 General Fungal Infection Statistics . 47 Table of Contents iii Copyright 2012 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited. Fungal Infection Risk 50 Description of Antifungal
9、 Products 52 Systemic Antifungals 52 Topical Antifungals 54 Market Overview 64 Total Market Size and Forecast 64 Antifungal Market by Product Type . 67 Antifungal Market by Geographical Region . 72 Market Analysis by Treated Condition . 75 Competitive Analysis 78 Leading Products 83 CHAPTER FOUR: AN
10、TIBACTERIAL DRUGS.85 Overview . 85 Classification of Antibacterial Organisms 85 Antimicrobial Spectrum 88 Bacterial Resistance 89 Principles of Anti- bacterial Therapy . 90 Combination Therapy and Prophylactic Use 92 Bacterial Infection Statistics . 93 Bacterial Infection Risk 96 Classifications of
11、Antibacterial Products 99 Aminoglycosides. 99 Carbapenems . 99 Cephalosporins 100 Macrolides. 101 Penicillins 101 Quinolones 102 Sulfonamides. 103 Tetracyclines . 103 Market Overview 118 Total Market Size and Forecast 119 Antibacterial Market by Product Type . 122 Antibacterial Market by Geographica
12、l Region . 129 Market Analysis by Treated Condition . 132 Competitive Analysis 136 Leading Products 142 CHAPTER FIVE: ANTIVIRAL DRUGS .145 Overview: Introduction to Viruses 145 Examples of Pathogenic Viruses 145 Virus Function and Life History . 146 Replication in DNA Viruses . 146 Replication of RN
13、A Viruses . 147 Replication in Retroviruses . 147 Table of Contents iv Copyright 2012 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited. Host Defenses Against Viruses . 148 Viral P
14、loys to Invade Host Cells and Circumvent Host Responses 149 Invasion of Host Cells . 149 Subversion of the Immune Response 150 Avoidance of Immune Detection and Attack by Killer Cells . 150 HIV and AIDS 151 Viral Infection Statistics . 153 Description of Antivirals Products 158 Nucleoside Analogs, T
15、ranscriptase Inhibitors and DNA Polymerase Inhibitors . 158 Protease Inhibitors 161 Other Antivirals 162 Market Overview 170 Total Market Size and Forecast 170 Antiviral Market by Product Type 173 Antiviral Market by Geographical Region . 179 Market Analysis by Treated Condition . 182 Competitive An
16、alysis 184 Leading Products 190 CHAPTER SIX: MARKET SUMMARY 193 Market by Product Segment (Antifungals, Antibacterials, Antivirals) . 194 CHAPTER SEVEN: CORPORATE PROFILES .198 Introduction . 198 Abbott Laboratories 200 Astellas 202 AstraZeneca 204 Bayer Healthcare Pharmaceuticals (Bayer Schering Ph
17、arma) 206 Bristol- Myers Squibb 208 Cubist 210 Daiichi Sankyo 212 Gilead Sciences . 213 GlaxoSmithKline 215 Johnson U.S. National Center for Health Statistics, Vital Statistics of the United States; CIA World Fact Book; Kalorama Information Two: Industry Trends 14 Copyright 2012 Kalorama Information
18、 Reproduction without prior written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited. Figure 2-2 Average Life Expectancy in Years by Country 1980 and 2009 Australia Australia Canada Canada China China France France Japan Japan Italy It
19、aly Germany Germany Mexico Mexico UK UK Turkey Turkey United States United States 55 65 75 85 95 19802009 Years Two: Industry Trends 15 Copyright 2012 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, in whole or in any part, is
20、 strictly prohibited. INFECTIONS AND DRUG RESISTANCE The resistance to drugs is considered a natural response to selective pressure of drug therapy. Although this is a natural course, the effects of resistance can be amplified or accelerated by several other factors including: abuse or misuse of ant
21、i- infectives; poor quality of drugs available (most common in under developed regions); poor patient compliance and reduced course of treatment due to cost constraints. Drug resistance is becoming more of an issue across the entire anti- infective continuum; however this is not a new concept. Resis
22、tances to antimicrobials were first recognized around 1950 starting with penicillin. Some of the most common resistant pathogens today include: Staphylococcus aureus Streptococcus Enterococcus Pseudomonas aeruginosa Clostridium difficile Salmonella and E. coli Acinetobacter baumannii Resistance is i
23、ncreasing and is concerning to the health industry because it is continuing to accelerate with more and more products being affected and the worlds tools for combating it decrease in power and number: Common deadly conditions showing resistance and forcing second and third- line therapy include resp
24、iratory infections, HIV/AIDS, diarrheal diseases, tuberculosis, and malaria. More than 90 percent of Staphylococcus aureus strains are resistant to penicillin and other related antibiotics; and many are resistant even to the newer methicillin- related drugs. There is an alarming rise in the incidenc
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- THE WORLD MARKET FOR ANTI-INFECTIVES ANTI INFECTIVES
链接地址:https://www.31doc.com/p-3800877.html